NEW YORK--(BUSINESS WIRE)--
H.C. Wainwright & Co., LLC (“HCW”) announced today the addition of one
Managing Director in Equity Research and three Vice Presidents in
Investment Banking to further enhance its Biotechnology Practice.
Swayampakula Ramakanth (“RK”), PhD. joins HCW in Equity Research as
Managing Director, Senior Biotechnology Analyst. Prior to joining HCW,
Dr. Ramakanth was a Junior Analyst at Jefferies and Merrill Lynch
covering large cap pharmaceuticals, and at First Albany and Rodman &
Renshaw covering biotechnology companies. Dr. Ramakanth previously
conducted bench research at Regeneron Pharmaceuticals, Inc. and directed
a preclinical drug development group. Dr. Ramakanth’s expertise consists
of companies in the oncology, infectious diseases, metabolic disorders
and animal health sectors. Dr. Ramakanth has over 10 years of experience
as a life sciences equity analyst and 7 years of biotechnology industry
Aileen M. Gibbons, PhD., Sean W. Hagerty, PhD. and Jeffery R. Smith,
PhD. join the HCW Healthcare Investment Banking team as Vice Presidents.
Dr. Gibbons earned her doctorate in liposomal formulation of protease
inhibitor proteins to treat inflammatory lung diseases from the Royal
College of Surgeons in Ireland. Dr. Hagerty earned his doctorate in
Cellular and Molecular Biology from NYU School of Medicine by
characterizing the role of TORC1 in Schwann cell dedifferentiation. Dr.
Smith earned his doctorate in Cancer Biology from the Gerstner
Sloan-Kettering Graduate School of Biomedical Sciences investigating the
role of Rho GTPases in cytoskeletal remodeling during breast cancer
proliferation and metastasis.
“We are pleased that RK, Aileen, Sean and Jeff have decided to join HCW
to further grow our biotechnology franchise,” commented Mark Viklund,
Chief Executive Officer of HCW. “RK joins Ren Benjamin, PhD. and Andrew
Fein in Biotechnology Equity Research to enhance HCW’s goal of providing
insightful investment ideas to our institutional investor clientele. The
addition of Aileen, Sean and Jeff to our investment banking practice
will enable HCW to deliver differentiated capital markets advice to our
biotechnology clients given their significant scientific achievements in
their fields of study.”
About H.C. Wainwright & Co., LLC
H.C. Wainwright & Co., LLC is an investment bank dedicated to providing
corporate finance, strategic advisory and related services to public and
private growth companies across multiple sectors and regions. The H.C.
Wainwright team has been the leader in the PIPE (private investment in
public equity) and RD (registered direct offering) transaction markets.
H.C. Wainwright was established in 1868 and is headquartered in New York
H.C. Wainwright & Co., LLC
Edward Silvera, 212-356-0500
Source: H.C. Wainwright & Co., LLC